232275-54-6

Basic information

• Product Name: Methyl 2,6-dichloro-4-hydroxybenzoate
• Synonyms: Methyl 2,6-dichloro-4-hydroxybenzoate
• CAS NO: 232275-54-6
• Molecular Formula: C₈H₆Cl₂O₃
• Molecular Weight: 221.03744
• Mol File: 232275-54-6.mol

Chemical Properties

• Boiling Point: 328.0±37.0 °C(Predicted)
• Appearance: /
• Density: 1.476±0.06 g/cm3(Predicted)
• PKA: 6.45±0.23(Predicted)
• CAS DataBase Reference: Methyl 2,6-dichloro-4-hydroxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2,6-dichloro-4-hydroxybenzoate(232275-54-6)
• EPA Substance Registry System: Methyl 2,6-dichloro-4-hydroxybenzoate(232275-54-6)

Safety Data

• Hazardous Substances Data: 232275-54-6(Hazardous Substances Data)

Upstream product

• 409127-35-1 4-tert-butoxycarbonylamino-2,6-dichloro-benzoic acid methyl ester 
• 232275-49-9 methyl 4-amino-2,6-dichlorobenzoate 
• 1321613-04-0 methyl 2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 14920-87-7 2,6-dichlorobenzoic acid methyl ester 
• 232275-53-5 methyl 4-bromo-2,6-dichlorobenzoate 
• 232275-51-3 4-bromo-2,6-dichloro-benzoic acid 

Relevant articles and documents

INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF

Disclosed herein, inter alia, are inhibitors of alpha 2 beta 1 integrin and methods of using the same.

Facile Synthesis of Halogen Decorated para -/ meta -Hydroxybenzoates by Iridium-Catalyzed Borylation and Oxidation

Hydroxybenzoates are an important class of phenols that are widely used as preservatives and antiseptics in the food and pharmaceutical industries. In this report, a facile preparation of 2,6- and 2,3-disubstituted 4/5-hydroxybenzoates by iridium-catalyze

Antagonists for treatment of CD/11CD18 adhesion receptor mediated disorders

Compounds of the general structure D-L-B-(AA), for example (A), that are useful for treating Mac-1 or LFA-1-mediated disorders such as inflammatory disorders, allergies, and autoimmune diseases are provided.

Inhibitors of α4 mediated cell adhesion

The present invention relates to a pharmaceutical composition comprising as an active ingredient a compound of formula (I), wherein Ring A is an aromatic or a heterocyclic ring; Q is a bond, carbonyl, lower alkylene, lower alkenylene, —O-(lower alkylene)-, etc.; n is 0, 1 or 2; Z is oxygen or sulfur, W is oxygen, sulfur, —CH═CH—, —NH— or —N═CH—; R1, R2and R3are the same or different and are hydrogen, halogen, hydroxyl, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted amino group, etc.; R4is tetrazolyl, carboxyl group, amide or ester; R5is hydrogen, nitro, amino, hydroxyl, lower alkanoyl, lower alkyl etc.; R6is selected from (a) a substituted or unsubstituted phenyl group, (b) a substituted or unsubstituted pyridyl group, (c) a substituted or unsubstituted thienyl group, (d) a substituted or unsubstituted benzofuranyl group, etc.; or a pharmaceutically acceptable salt thereof.